Lead Product(s) : Thykamine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Devonian's Thykamine™ Shows Positive Gene Expression Results for Fibrosis
Details : Thykamine is an innovative botanical pharmaceutical product, which is currently being evaluated for the treatment of gene expression associated with fibrosis.
Product Name : PUR0110
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
February 18, 2025
Lead Product(s) : Thykamine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DispersinB
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Preclinical
Sponsor : NRC IRAP
Deal Size : $0.1 million
Deal Type : Funding
Kane Biotech to Participate in a Multinational Corporate Collaboration Project
Details : The funding will be used to develop a proof-of concept for its DispersinB Wound Gel, antibiofilm enzyme-based gel for treating chronic wounds.
Product Name : DispersinB
Product Type : Enzyme
Upfront Cash : Undisclosed
March 10, 2024
Lead Product(s) : DispersinB
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Sponsor : NRC IRAP
Deal Size : $0.1 million
Deal Type : Funding
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Preclinical
Sponsor : AMRMC
Deal Size : $0.7 million
Deal Type : Funding
Details : The funds will support preclinical study of ALPHA-1062, an inactive galantamine prodrug and a new generation acetylcholinesterase inhibitor being developed for Alzheimer’s disease, to reduce blast mild Traumatic Brain Injury induced functional deficit ...
Product Name : Alpha-1062
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 06, 2023
Lead Product(s) : Galantamine Benzoate
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Sponsor : AMRMC
Deal Size : $0.7 million
Deal Type : Funding
Lead Product(s) : Oat Beta Glucan
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Preclinical
Sponsor : Angiogenesis Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Oat-based bioactives BG and AV exhibited potential to improve regenerative wound healing, reduce inflammation, promote angiogenesis, and reduce scar formation.
Product Name : Juvente
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 05, 2023
Lead Product(s) : Oat Beta Glucan
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Sponsor : Angiogenesis Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Research studies have shown that Ketarx (ketamine) lessens the injury from ischemia/reperfusion by inhibiting NF-κB thereby suppressing the production of such proinflammatory cytokines as IL-6 and TNF-α.
Product Name : Ketarx
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 15, 2022
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DispersinB
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Preclinical
Sponsor : US Department of Defense
Deal Size : $2.7 million
Deal Type : Funding
Details : The funding supplements the clinical development of Kane’s DispersinB Hydrogel to treat biofilm-mediated antimicrobial resistance in non-healing chronic wounds. The DispersinB is a hydrogel wound dressing containing the enzyme DispersinB and the gellin...
Product Name : DispersinB
Product Type : Enzyme
Upfront Cash : Undisclosed
April 10, 2022
Lead Product(s) : DispersinB
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Sponsor : US Department of Defense
Deal Size : $2.7 million
Deal Type : Funding
Lead Product(s) : Psilocybine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Revive Therapeutics Files for FDA Orphan Drug Designation for Psilocybin in Traumatic Brain Injury
Details : In preclinical studies it was found that psilocybin, given after injury, improved cognitive function in TBI mice. Also, there were no adverse effects observed with psilocybin.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 29, 2021
Lead Product(s) : Psilocybine
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Revive is expanding its product pipeline by leveraging its FDA orphan drug designation for cannabidiol in the prevention of ischemia and reperfusion injury from organ transplantation.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 20, 2020
Lead Product(s) : Cannabidiol
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable